40 / 74 · 0:51 · Original AXON film
Selank
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Selank | A small clinical comparison
Selank has been studied in people, but study design still matters. One 2008 report compared it with medazepam in patients with anxiety-related diagnoses. [1]
62 PATIENTS | Active comparator
The report included sixty-two patients and described similar anxiety improvements between groups. An active-comparator result alone does not establish broad effectiveness or formal equivalence. [1]
Read the methods and uncertainty
The indexed abstract gives limited detail about methods and uncertainty. Larger, well-described trials and safety follow-up are needed to support stronger conclusions. [1]
Safety evidence remains incomplete
FDA separately notes missing safety information and possible immune-reaction concerns for compounded Selank acetate. The clinical report should not be read as a guarantee of safety. [2]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Zozulia et al. (2008): Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in generalized anxiety disorders and neurasthenia →Sixty-two patients, active medazepam comparator and reported results; limited abstract-level methodological detail.
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks →Safety-information and potential immunogenicity concerns; withdrawal is not approval.
